Barry Allan Effron, MD
- Coronary Artery Disease (CAD)
- Lipid Management
- Preventive Cardiovascular Medicine
- Valvular Heart Disease
Patient Satisfaction Reviews
4.9 out of 5
Patient Comments (4)
Reviewed On 8/19/2018
Dr. Effron has ALWAYS provided excellent care, concern and advice about my health. He is very easy to talk to and thru all concerns about my *****. By far, he is the BEST Dr. I have at UH.
Reviewed On 8/12/2018
Dr. Effron counseled me on my eating and exercise habits. He suggested loss of weight, He said cholesterol readings were excellent. He ordered follow-up test on my heart. All of this was a good experience.
Reviewed On 5/28/2018
All the help was great
Reviewed On 5/27/2018
Dr. Effron is the best!
- Cardiovascular Disease - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Research Fellowship | Cardiovascular Disease
Cardiovascular Disease - University Of Wisconsin-Madison (1984 - 1985)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - University Hospitals Of Cleveland (1983 - 1984)
Fellowship | Cardiovascular Disease
Cardiovascular Disease - University Hospitals Of Cleveland (1981 - 1983)
Residency | Internal Medicine
Internal Medicine - University Hospitals Of Cleveland (1980 - 1981)
Residency | Internal Medicine
Internal Medicine - Ohio State University Hospital (1979 - 1980)
Internship | Internal Medicine
Internal Medicine - Ohio State University Hospital (1978 - 1979)
The Ohio State University College Of Medicine (1978)
Cornell University (1975)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Barry Allan Effron disclosed the following Outside Relationships with Industry:
- - Boehringer Ingelheim Pharmaceutical, Inc. (BIPI) - Consulting
- - Amgen, Inc. - Honoraria